Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C-Results of a Multicenter EpiTer-2 Study.

Autor: Pawlowska M; Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University, 87-100 Torun, Poland.; Department of Paediatrics, Infectious Diseases and Hepatology, Voivodeship Infectious Observation Hospital in Bydgoszcz, 85-030 Bydgoszcz, Poland., Dobrowolska K; Collegium Medicum, Jan Kochanowski University, 25-317 Kielce, Poland., Moppert J; Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University, 87-100 Torun, Poland.; Department of Paediatrics, Infectious Diseases and Hepatology, Voivodeship Infectious Observation Hospital in Bydgoszcz, 85-030 Bydgoszcz, Poland., Pokorska-Śpiewak M; Department of Children's Infectious Diseases, Medical University of Warsaw, 01-201 Warsaw, Poland.; Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, 01-201 Warsaw, Poland., Purzynska M; Pomeranian Centre of Department of Infectious Diseases and Observation for Children, Smoluchowskiego 18, 80-214 Gdansk, Poland., Marczynska M; Department of Children's Infectious Diseases, Medical University of Warsaw, 01-201 Warsaw, Poland.; Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, 01-201 Warsaw, Poland., Zarebska-Michaluk D; Department of Infectious Diseases and Allergology, Jan Kochanowski University, 25-317 Kielce, Poland., Flisiak R; Department of Infectious Diseases and Hepatology, Medical University of Białystok, 15-540 Bialystok, Poland.
Jazyk: angličtina
Zdroj: Journal of clinical medicine [J Clin Med] 2023 Nov 06; Vol. 12 (21). Date of Electronic Publication: 2023 Nov 06.
DOI: 10.3390/jcm12216949
Abstrakt: The aim of the study was to analyze the effectiveness and safety of anti-HCV treatment based on a pangenotypic direct-acting antiviral (DAA) regimen with glecaprevir/pibrentasvir (GLE/PIB) in children. The multi-center study was conducted in HCV-infected children who were treated in the period from November 2022 to January 2023. The analysis included 23 pediatric patients with a mean (SD) age of 9.61 (3.68) years. The cohort included 13 girls and 10 boys. The most common HCV genotypes were GT1b ( n = 9, 39.1%), GT1a ( n = 6, 26.1%) and GT3 ( n = 5, 21.7%). The SVR was assessed at 12 weeks after the end of treatment and was 100% for both girls and boys. The conducted study showed a very good tolerance of the treatment in the entire analyzed group and confirmed a very high efficacy and safety for 8-week treatment with GLE/PIB in children over three years of age. It seems that our study is the first on the real-world use of an 8-week GLE/PIB pangenotypic therapy in a group of children aged 3-12 years and the first in Europe for adolescents aged 12-17.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje